MedTrace Logo

Lapatinib and Circulating Tumor Cells in Breast Cancer

NCT00694252 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-09-28

No results posted yet for this study

Summary

This study will evaluate the efficacy of lapatinib in eradicating chemo- resistant tumour cells circulating in the blood of patients with breast cancer.

Conditions

Interventions

DRUG

Lapatinib

Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.

Sponsors & Collaborators

  • University Hospital of Crete

    lead OTHER

Principal Investigators

  • Sofia Aggelaki, MD · University Hospital of Crete

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00694252 on ClinicalTrials.gov